Compounds > tadalafil
Page last updated: 2024-09-02

tadalafil and 3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene

tadalafil has been researched along with 3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene in 1 studies

Compound Research Comparison

Studies
(tadalafil)		Trials
(tadalafil)		Recent Studies (post-2010)
(tadalafil)		Studies
(3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene)		Trials
(3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene)		Recent Studies (post-2010) (3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene)
1,7423921,08924017

Protein Interaction Comparison

ProteinTaxonomytadalafil (IC50)3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene (IC50)
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)1.8
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)1.28
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)1.2843

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chai, S; Chen, S; Deng, L; Du, K; Shen, R; Sun, H; Sun, T; Xi, M; Xie, M1

Reviews

1 review(s) available for tadalafil and 3-(n,n-dimethylsulfonamido)-4-methyl-nitrobenzene

ArticleYear
Therapeutic potential of phosphodiesterase inhibitors for cognitive amelioration in Alzheimer's disease.
    European journal of medicinal chemistry, 2022, Mar-15, Volume: 232

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Alzheimer Disease; Animals; Cognition; Cyclic GMP; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases

2022